{"id":{"repo_id":"baylor","oai_identifier":"oai:baylor-ir.tdl.org:2104/14322"},"canonical_url":"https://search.dev.ndltd.org/etd/baylor/oai:baylor-ir.tdl.org:2104/14322","repository":{"repo_id":"baylor","name":"Baylor University","base_url":"https://baylor-ir.tdl.org/server/oai/request"},"display":{"title":"The impact of the endorsing channel upon physicians' decisions to adopt clustered and unclustered drug treatment innovations.","abstract":"This thesis tests two hypotheses. First, the more credible an endorsing channel is perceived, the greater probability that a physician will choose to adopt a drug treatment innovation. An Endorsing Channel Influence Scale is reported for people interested in predicting whether an endorsing channel is likely to result in a decision to prescribe a given drug treatment innovation. The minimally sufficient endorsing channel's probable impact on adoption is derived from the Endorsing Channel Influence Scale. The results of this scalogram counter notions that interpersonal channels are associated with a greater likelihood in promoting adoption of an innovation than mass communication channels. The second hypothesis is a clustered drug treatment innovation will result in a lower minimally sufficient endorsing channel threshold than a non-clustered drug treatment innovation. This hypothesis is tested by comparing the mean scores for clustered and non-clustered situations. A t-test resulted in rejection of this hypothesis.","abstract_html":"This thesis tests two hypotheses. First, the more credible an endorsing channel is perceived, the greater probability that a physician will choose to adopt a drug treatment innovation. An Endorsing Channel Influence Scale is reported for people interested in predicting whether an endorsing channel is likely to result in a decision to prescribe a given drug treatment innovation. The minimally sufficient endorsing channel's probable impact on adoption is derived from the Endorsing Channel Influence Scale. The results of this scalogram counter notions that interpersonal channels are associated with a greater likelihood in promoting adoption of an innovation than mass communication channels. The second hypothesis is a clustered drug treatment innovation will result in a lower minimally sufficient endorsing channel threshold than a non-clustered drug treatment innovation. This hypothesis is tested by comparing the mean scores for clustered and non-clustered situations. A t-test resulted in rejection of this hypothesis.","abstract_has_math":false,"creators":["Arquette, Toby James."],"institution":"Baylor University.","degree_name":"M.A.","degree_level":"Masters","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Loges, William E."],"committee_chairs":[],"committee_members":[],"year":1998,"date_issued":"1998-05","date_published":"1998-05","updated_at":"2026-07-24T01:08:02Z","subjects":["Communication -- Network analysis.","Diffusion of innovations."],"languages":["en"],"rights":["Baylor University works are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. Contact libraryquestions@baylor.edu for inquiries about permission."],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2104/14322","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Loges, William E."]},{"key":"dc:creator","label":"Author","values":["Arquette, Toby James."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-03-05T05:12:20Z"]},{"key":"dc:date.issued","label":"Date","values":["1998-05"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Masters"]},{"key":"thesis:degree_name","label":"Degree Name","values":["M.A."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Baylor University."]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Communication -- Network analysis.","Diffusion of innovations."]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Baylor University works are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. Contact libraryquestions@baylor.edu for inquiries about permission."]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2104/14322"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["This thesis tests two hypotheses. First, the more credible an endorsing channel is perceived, the greater probability that a physician will choose to adopt a drug treatment innovation. An Endorsing Channel Influence Scale is reported for people interested in predicting whether an endorsing channel is likely to result in a decision to prescribe a given drug treatment innovation. The minimally sufficient endorsing channel's probable impact on adoption is derived from the Endorsing Channel Influence Scale. The results of this scalogram counter notions that interpersonal channels are associated with a greater likelihood in promoting adoption of an innovation than mass communication channels. The second hypothesis is a clustered drug treatment innovation will result in a lower minimally sufficient endorsing channel threshold than a non-clustered drug treatment innovation. This hypothesis is tested by comparing the mean scores for clustered and non-clustered situations. A t-test resulted in rejection of this hypothesis."]},{"key":"dc:format.mimetype","label":"Dc Format Mimetype","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["The impact of the endorsing channel upon physicians' decisions to adopt clustered and unclustered drug treatment innovations."]}]}],"canonical_facts":{"dc:contributor.advisor":["Loges, William E."],"dc:creator":["Arquette, Toby James."],"dc:date.accessioned":["2026-03-05T05:12:20Z"],"dc:date.issued":["1998-05"],"dc:description.abstract":["This thesis tests two hypotheses. First, the more credible an endorsing channel is perceived, the greater probability that a physician will choose to adopt a drug treatment innovation. An Endorsing Channel Influence Scale is reported for people interested in predicting whether an endorsing channel is likely to result in a decision to prescribe a given drug treatment innovation. The minimally sufficient endorsing channel's probable impact on adoption is derived from the Endorsing Channel Influence Scale. The results of this scalogram counter notions that interpersonal channels are associated with a greater likelihood in promoting adoption of an innovation than mass communication channels. The second hypothesis is a clustered drug treatment innovation will result in a lower minimally sufficient endorsing channel threshold than a non-clustered drug treatment innovation. This hypothesis is tested by comparing the mean scores for clustered and non-clustered situations. A t-test resulted in rejection of this hypothesis."],"dc:format.mimetype":["application/pdf"],"dc:identifier.uri":["https://hdl.handle.net/2104/14322"],"dc:language.iso":["en"],"dc:rights":["Baylor University works are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. Contact libraryquestions@baylor.edu for inquiries about permission."],"dc:subject":["Communication -- Network analysis.","Diffusion of innovations."],"dc:title":["The impact of the endorsing channel upon physicians' decisions to adopt clustered and unclustered drug treatment innovations."],"dc:type":["Thesis"],"thesis:degree_level":["Masters"],"thesis:degree_name":["M.A."],"thesis:institution_name":["Baylor University."]},"updated_at":"2026-07-24T01:08:02Z"}